The Contribution of Digital Remote Monitoring to Improving the Effectiveness of Treatment in Patients with Chronic Heart Failure with Reduced Ejection Fraction: data after a 6-week follow-up period (Preprint)

• DOI: 10.2196/preprints.76963
• Publication Date: 2025-05-05T16:40:09Z
• Authors: Maria Kozhevnikova; Aleksei Emelianov; Elena Zheleznykh; Nikolay Pavlov; Natalia Khabarova; Yuri Belenkov
• Keywords: Preprint; Fraction (chemistry)

<sec> <title>BACKGROUND</title> The main strategy for the management of heart failure (HF) patients with reduced ejection fraction is guideline-directed medical therapy (GDMT). Remote GDMT optimization using digital monitoring and guideline support appears to be a promising method. Therefore, Contribution Digital Monitoring Improving Effectiveness Treatment in Patients Chronic Heart Failure Reduced Ejection Fraction (BOT-IMPROVE-HF) was conducted. </sec> <title>OBJECTIVE</title> aim study assess effectiveness rapid titration reach target doses reduce combined endpoint all-cause mortality HF decompensation. <title>METHODS</title> This research introduces multifaceted approach consisting following components: vital signs data sharing questionnaire via free mobile messaging tool (chatbot), weekly recommendations optimize 6 weeks. <title>RESULTS</title> A total 66 were randomized between remote (RM) group usual care (UC) 27 October 2023 December 2024. Thirty-three included each group. Twenty-six RM all UC completed 6-week follow-up period taken primary analysis. There significant increase median dose group, while there no changes or down-titrations [angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors P &lt; 0.001*); β-blockers (P = 0.0001*); mineralocorticoid antagonists 0.005*)]. diuretics significantly 0.01*) did not change after weeks 0.9). decompensation rates higher than (16 (2 mortality, 14 decompensations) vs 2 (0 decompensations), 0.0003*). No difference observed systolic blood pressure 0.9), rate 0.06), estimated glomerular filtration 0.22) potassium level 0.33). <title>CONCLUSIONS</title> article shows results period. BOT-IMPROVE-HF trial met its outcome achieved intervention safe, treatment complications registered. <title>CLINICALTRIAL</title> ClinicalTrials.gov NCT06304753